Compare GSK plc (GSK) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sibanye Stillwater Ltd — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Sibanye Stillwater Ltd trades at $10 (market cap $6.88B). The key difference: GSK plc is far larger — about 13.4× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (8.17%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Sibanye Stillwater Ltd for 51 Days on average.
| GSK | SBSW | |
|---|---|---|
Market Cap | $91.88B | $6.88B |
Volume | 7,730,529 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $21.12 |
52-Week Low | $43.24 | $8.00 |
Typical Hold Time | 93 Days | 51 Days |
Enterprise Value | $111.88B | $7.78B |
Dividend Yield | 3.9% | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SBSW trades at $10.00, up 3.31% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company shows strong revenue growth to $129.68B in 2025 and improved cash flow, though net income remains negative. Analyst consensus is moderately bullish with a $14.25 price target, supported by recent institutional buying activity and positive coverage of H1 2026 results.
The outlook suggests potential upside based on valuation metrics (P/E 8.12, P/S 0.7) and projected 2026 profitability, but risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Investors should weigh the attractive valuation against operational execution challenges in the mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
